Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project

Beatrice J. Edwards1 • Dennis W. Raisch2 • Smita S. Saraykar1 • Ming Sun1 • Josh A. Hammel3 • Hai T. Tran4 • Nathaniel Wehr1 • Rasha Arabyat2 • Dennis P. West3,5

Abstract

Background On 30 January 2012, the US FDA approved vismodegib (Erivedge®, Genentech, CA, USA) for the management of both metastatic and locally advanced basal cell carcinoma.

Objective Our objective was to identify evidence of hepatotoxicity with vismodegib in the FDA Adverse Event Reporting System (FAERS) in treated patients in two National Cancer Institute Comprehensive Cancer Centers.

Methods FAERS was searched for reports dated 1 January 2009 through 31 December 2015 using terms including hedgehog pathway and vismodegib and hepatic-related terms such as liver, jaundice, and hepatitis, among others. Disproportionality analyses with estimates of proportional reporting ratio and empirical Bayesian geometric mean were conducted. A comprehensive literature review was conducted, and the clinical databases at the University of Texas MD Anderson Cancer Center and Robert H. Lurie Comprehensive Cancer Center of Northwestern University were searched.

Results Two cases of severe liver dysfunction were published (Common Terminology Criteria for Adverse Events [CTCAE] class III), and 94 reports of adverse events (AEs) were detected in FAERS, 35 of which were serious AEs. Safety notifications related to hepatotoxicity have not been issued by the manufacturer or the FDA, although vismodegib is listed in LiverTox and the European Medicines Agency website.

Conclusion We identified a detectable safety signal for hepatotoxicity for vismodegib within 4 years of FDA approval. Vismodegib should be used in patients with severe liver disease only after careful consideration, and concomitant hepatotoxic medications should be avoided. Rapid dissemination of such safety concerns is expected to result in fewer serious hepatotoxic AEs and more optimal outcomes for patients with cancer receiving vismodegib.

Electronic supplementary material The online version of this article (doi:10.1007/s40268-016-0168-2) contains supplementary material, which is available to authorized users.

Banner Beatrice J. Edwards
BEdwards@mdanderson.org

1 Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, 1400 Pressler Dr., Unit # 1465, Houston, TX 77030, USA

2 College of Pharmacy, University of New Mexico, Albuquerque, NM, USA

3 Department of Dermatology, Northwestern University, Chicago, IL, USA

4 Thoracic, Head and Neck Medical Oncology Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

5 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA
1 Introduction

About eight in ten skin cancers are basal cell carcinomas (BCCs) [1], making it the most common type of skin cancer, arising from the lower layer of the skin. In 2014, more than 2 million estimated new cases and 1000 deaths occurred in the USA [2]. Surgery followed by radiation offers the most effective and efficient means for cure. Therapies such as 5-flurouracil, imiquimod, photodynamic therapy, or vigorous cryotherapy can be considered as alternative treatments for individuals with low-risk superficial BCC [3].

On 30 January 2012, the US FDA approved vismodegib for the treatment of recurrent, locally advanced, or metastatic BCC, based primarily on the results observed in a single-arm parallel-cohort international trial [4]. An overall response rate of 43 and 30% was seen in patients with localized and metastatic BCC [5].

The most common adverse events (AEs) associated with vismodegib reported in randomized controlled trials (RCTs) were muscle spasms, alopecia, dysgeusia, weight loss, fatigue, loss of appetite, and upper respiratory tract infections [4, 6]. One case of severe hepatotoxicity with vismodegib was reported in an 83-year-old female subject [7]. This individual’s medical history included hypertension, atrial fibrillation, and chronic obstructive pulmonary disease but no evidence of prior liver abnormalities. After 1 week of treatment, she developed nausea and emesis and was hospitalized. Liver function tests revealed a cholestatic pattern of hepatotoxicity, and liver biopsy exhibited non-specific cholestasis with portal fibrosis. Other RCTs in advanced BCC [8] and ovarian cancer [9] have listed, less commonly, elevation of hepatic enzymes and abdominal pain.

The FDA Adverse Event Reporting System (FAERS) is a self-reported and voluntary database of AEs and medication errors reported to the FDA. It is designed to support the FDA’s post-marketing safety surveillance program for drugs and therapeutic biological products. FAERS data can be used to identify post-marketing safety signals. A safety signal is defined by the Working Group VIII of the Council for International Organizations of Medical Sciences (CIOMS VIII) as “Information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, that is judged to be of sufficient likelihood to justify further verification” [10]. Limitations include no proven causal relationship between events and a certain product and potential reporting bias [11].

The Research on Adverse Drug events And Reports (RADAR) project has received National Cancer Institute (NCI) and National Science Foundation (NSF) funding for pharmacovigilance activities. Based at Northwestern University, RADAR was first initiated in 1998 by a multidisciplinary investigator team that systematically investigated and disseminated information describing serious and previously unrecognized adverse drug and device reactions (ADRs) [12]. The purpose of this study was to determine whether a safety signal for vismodegib-related hepatotoxic AEs is detectable in FAERS and to search the clinical databases of two NCI-designated Comprehensive Cancer Centers in two large urban settings (Houston and Chicago, USA), The University of Texas MD Anderson Cancer Center and R.H. Lurie Comprehensive Cancer Center (RHLCCC) of Northwestern University, respectively.

2 Methods

This retrospective study was approved by the Institutional Review Boards of MD Anderson Cancer Center and Northwestern University. RADAR methodology has been previously described in detail [12]. We searched FAERS for vismodegib and adverse liver event as combined terms from 1 January 2009 through 31 December 2015. All hepatic cases were identified through a search including ascites, hepatobiliary disease, liver toxicity, hepatitis, and cholestasis, among others. Complete search terms are listed in Appendix I in the Electronic Supplementary Material.

Within FAERS, we calculated disproportionate reporting of hepatic dysfunction using proportional reporting
ratios (PRRs) with 95% confidence intervals (CIs). PRRs determined whether the proportion of FAERS cases with hepatic dysfunction was higher in patients receiving vismodegib than in those receiving other drugs. The PRR is a statistical aid that generates signals based on a proportional approach, which also acknowledges the stability of a large database. PRRs involve calculation of the proportions of specified reactions for drugs of interest, with the comparator being the proportions of the specified reactions reported among all other drugs in the database. Judgment about the existence of a signal and its strength is made based on three pieces of information: the PRR, the chi-squared value of the data, and the number of cases. A signal is defined as a PRR of ≥2, a chi-squared value ≥4, and three or more cases reported to FAERS [12, 13].

The clinical databases at MD Anderson Cancer Center and RHLCCC were queried to detect individuals exposed to vismodegib. Medical records of these cases were reviewed, and data on demographics (age, sex, race/ethnicity, type of cancer) and liver function tests were collected. In addition, three major electronic databases were searched (MEDLINE, PubMed, and Embase) for peer-reviewed articles published between 1970 and 31 March 2014 using terms such as vismodegib, GDC-0449, sonic hedgehog, neoplasm, and clinical trials. The literature review obtained information on the results of clinical trials of vismodegib reporting on efficacy and adverse effects. We also searched websites and safety databases maintained by the FDA and other major international regulatory agencies.

Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 was used as toxicity grading criteria for AE reporting. A grading (severity) scale is provided for each AE term (grade 1: mild AE; grade 2: moderate AE; grade 3: severe AE; grade 4: life-threatening or disabling AE; grade 5: death related to AE) [14]. For hepatotoxicity cases detected within FAERS, concomitant drugs were reviewed; those with significant hepatic metabolism were identified based on information contained within multiple databases [15].

3 Results

3.1 FDA Adverse Event Reporting System (FAERS) Results

In total, 94 FAERS cases were reported as having at least one AE of liver dysfunction, with 35 reports including terms demonstrating severe hepatotoxicity (Table 1), all of which were reported to FAERS by the sponsor. Of 35 reports, 20 were serious AEs (SAEs) resulting in hospitalization or death. Other AEs with these cases included dysphagia, abdominal discomfort, and cognitive disorders. The mean age of all 35 individuals was 60 years (range 0–98); 16 were female and 16 were male (of the 32 FAERS cases in which sex was reported). Comorbidities were infrequently reported and included hypertension (3/35), diabetes mellitus (2/35), hypothyroidism (1/35), and acute respiratory distress syndrome (1/35). Signal-detection analyses resulted in PRRs of 2.71 (95% CI 2.3–3.2) among all hepatic dysfunction cases and 2.24 (95% CI 1.7–2.9) among serious hepatotoxicity cases, and reflect a significant safety signal.

3.2 University of Texas MD Anderson Cancer Center and Robert H. Lurie Cancer Center Results

In total, 15 patients received vismodegib in two cancer centers: for BCC (n = 13) and for medulloblastoma (n = 2). Two cases experienced elevated alkaline phosphatase (twofold elevation).

4 Discussion

We ascertained that hepatic events associated with vismodegib in FAERS produced a safety signal. This association was previously described in the study by Ventarola and Silverstein [16]. We identified an increasing incidence over the extended study period. The first case was reported prior to FDA approval in 2011, and there has been an upward trend in cases reported to FAERS over the last 4 years (Fig. 1). It has been reported that a median of 7 years post-marketing elapses before newly detected SAEs are announced by pharmaceutical suppliers and/or the FDA [17], but this report of vismodegib-associated hepatotoxicity is being disseminated within 4 years of approval. The importance of systematic interrogation and analyses with large databases such as FAERS is made evident in that, in two NCI-designated comprehensive cancer centers, initial interrogation showed no detectable reports of hepatotoxicity. Such a finding is not unexpected, given the small number of treated patients (n = 15) in two of the NCI-designated 41 comprehensive cancer centers. Since hepatotoxicity may progress to be severe and/or life threatening, further exploration of this important association is essential. According to the NCI, only about 15% of US cancer patients are diagnosed and treated at the nation’s major academic-based cancer centers, and the large remainder may not be easily tracked for outcomes [18]. Moreover, since FAERS case reports are de-identified, it is not practical to ascertain, and/or contact the initial reporter for, further clinical information and outcomes. Moreover, FAERS reports of vismodegib-
Table 1  Cases of hepatotoxicity attributed to vismodegib in the FDA Adverse Event Reporting System

| Report date | Age (sex) | Cancer type | Concomitant drugs with hepatic metabolism | Co-morbidities | Adverse events | CTCAE | Outcomes | Vismodegib administration time course (days) |
|-------------|-----------|-------------|------------------------------------------|----------------|----------------|-------|----------|---------------------------------------------|
| 2012        | 83 (F)    | BCC         | Lanoxin, Lasix, Theophylline             | NA             | Hepatocellular injury | 4     | Hospitalization | NA                                          |
| 2012        | 84 (M)    | BCC         | NA                                       | NA             | Hepatitis | 4     | Life threatening | 47                                          |
| 2012        | 63 (F)    | BCC         | Cymbalta, Levothyroxine                  | NA             | Hepatotoxicity | 3     | Hospitalization | 55                                          |
| 2012        | 58 (NA)   | Pancreatic carcinoma metastatic          | Oxycontin      | NA             | Ascites   | 5     | Death, hospitalization | 218                                         |
| 2012        | 59 (M)    | Adenocarcinoma pancreas                  | NA             | NA             | Ascites   | 3     | Hospitalization | 5                                           |
| 2012        | 41 (F)    | BCC         | NA                                       | NA             | Hepatitis | 3     | Hospitalization | 60                                          |
| 2013        | NA (F)    | BCC         | NA                                       | NA             | DILI      | NA    | Other          | NA                                          |
| 2013        | 50 (M)    | BCC         | NA                                       | NA             | Hepatitis | 4     | Hospitalization | NA                                          |
| 2013        | 76 (M)    | BCC         | Uroxatral, Zocor, Zyloprim               | NA             | Hepatotoxicity | 4     | Hospitalization | NA                                          |
| 2013        | 59 (M)    | BCC         | Advair, Premarin                         | NA             | Hepatitis | 3     | Hospitalization | NA                                          |
| 2013        | 68 (F)    | NA          | Diovan, Vibramycin                       | NA             | DILI      | NA    | Other          | NA                                          |
| 2013        | NA        | NA          | NA                                       | NA             | Liver disorder | NA    | Other          | NA                                          |
| 2014        | 75 (M)    | BCC         | NA                                       | NA             | Hepatocellular injury | 4     | Disability other | 52                                          |
| 2014        | 79 (F)    | AML         | Augmentin, Diovan, Dulcolax, Hydrea, Hydrochlorothiazid, Lipitor, Nystatin, Tenormin, Zyloprim | NA | Autoimmune thyroiditis, hyperlipidemia, hypertension | 3 | Hospitalization | NA                                          |
| 2014        | 98 (F)    | BCC         | NA                                       | NA             | DILI      | NA    | Other          | 48                                          |
| 2014        | 90 (M)    | BCC         | Amoxicillin, Aspirin, Kerlone, Lotensin, Lozol, Norvasc, Rutosocorbin, Tricor, Ultracet, Vinpocetine, Zocor | Hypercholesterolemia, hyperlipidemia, hypertension | DILI | 3 | Hospitalization | 66                                          |
| 2014        | 72 (M)    | BCC         | Cialis, Diovan, Norvasc                   | NA             | Cholestatic liver injury | 3 | Hospitalization | NA                                          |
| 2014        | 68 (M)    | BCC         | Amaryl, Bactrim, Capoten, Cardizem, Coumadin, Glucophage, Jentadueto, Lantus, Pravachol, Ranexa, Xarelto | Hyperlipidemia, hypertension, T2DM | DILI | 3 | Hospitalization | 217                                         |
| 2014        | 88 (M)    | BCC         | NA                                       | NA             | Hepatitis cholestatic | 3 | Hospitalization | NA                                          |
Table 1 continued

| Report date | Age\(^a\) (sex) | Cancer type | Concomitant drugs with hepatic metabolism | Co-morbidities | Adverse events | CTCAE | Outcomes | Vismodegib administration time course (days) |
|-------------|-----------------|-------------|------------------------------------------|----------------|----------------|-------|----------|---------------------------------------------|
| 2015 70 (M)  | NA              | BCC         | NA                                       | NA             | Hepatotoxicity | NA    | Other    | NA                                          |
| 2015 72 (M)  | NA              | BCC         | NA                                       | NA             | Liver injury   | NA    | Other    | NA                                          |
| 2015 48 (F)  | NA              | NA          | NA                                       | NA             | Hepatic failure| NA    | Other    | NA                                          |
| 2015 0 (F)   | NA              | NA          | NA                                       | NA             | Liver disorder | NA    | Other    | NA                                          |
| 2015 56 (M)  | NA              | NA          | NA                                       | NA             | Hepatobiliary disease | 5 | Hospitalization, death | 18 |
| 2015 70 (F)  | BCC             | NA          | Diosmectite, Elavil, Hexaquine, Miralax, Nexium, Tylenol, Ultrace, Ultram, Vitabact | DM             | Ascites | 3 | Hospitalization | 853 |
| 2015 68 (M)  | NA              | NA          | Capoten, Cardizem, Colace, Diabeta, Eliquis, Glucophage, Jentadueto, Lantus, Lasix, Lopressor, Nitroglycerin, Plavix, Pravachol, Protonix, Ranexa, Sulfamethoxazole | NA             | Acute hepatic failure | 5 | Hospitalization, life threatening, death | 240 |
| 2015 83 (F)  | BCC             | NA          | NA                                       | NA             | Hepatocellular injury | NA | Other    | 81                                          |
| 2015 0 (F)   | NA              | BCC         | NA                                       | NA             | Hepatotoxicity | NA    | Other    | NA                                          |
| 2015 0 (M)   | NA              | BCC         | Diovan, Fusidic Acid, Glucophage, Januvia, Lipitor, Robaxacet, Sectral, Symbicort, Ventolin, Veramyst, Voltaren | NA             | Hepatitis | 3 | Hospitalization | NA |
| 2015 76 (F)  | NA              | BCC         | Enbrel, Hyzaar                            | NA             | Hepatitis toxic | 3 | Hospitalization | 21 |
| 2015 89 (F)  | NA              | BCC         | NA                                       | NA             | Hepatitis      | NA    | Other    | NA                                          |
| 2015 0 (M)   | NA              | BCC         | NA                                       | NA             | Liver disorder | 3 | Hospitalization | NA |
| 2015 71 (F)  | BCC             | NA          | NA                                       | NA             | Hepatitis acute | NA | Other    | NA                                          |
| 2015 57 (M)  | BCC             | NA          | NA                                       | NA             | Hepatic failure | 5 | Death    | NA                                          |
| 2015 0 (M)   | BCC             | NA          | NA                                       | NA             | Hepatitis cholestatic | NA | Other    | NA                                          |

Assessment based on FAERS summary data. Since FAERS case data are often incomplete, missing data are shown as ‘NA’.

AML acute myeloid leukemia, BCC basal cell carcinoma, CTCAE Common Terminology Criteria for Adverse Events, Version 4.0, DILI drug-induced liver injury, DM diabetes mellitus, F female, M male, NA not available, T2DM type 2 diabetes mellitus

\(^a\) Age is presented in years
associated hepatotoxicity typically do not provide detail on related comorbidities such as prior liver abnormalities or alcohol abuse.

Some possible mechanisms of drug-related hepatotoxicity include disruption of the cell membrane and drug binding to cell protein, leading to cell death; cell apoptosis; inhibition of cell mitochondria function; cellular pathway inhibition; and abnormal bile flow leading to cholestasis and jaundice. Moreover, obesity and malnutrition, pregnancy, history of drug reactions, and pre-existing liver disease are factors that lead to susceptibility to hepatotoxicity [19]. Liver abnormalities may also include etiological factors such as nonalcoholic steatohepatitis (NASH), medication use, alcohol use, and chronic liver disease, among others [20].

In published RCTs, vismodegib resulted in elevated alanine aminotransferase levels compared with the placebo arm [21]. SAEs (CTCAE grade 3–4) were seen in two participants in an ovarian cancer RCT [9]. Hedgehog signaling has generally been considered inactive in healthy adult hepatocytes. Paracrine connections with hepatic epithelial cells are important for embryonic development, cell proliferation, and recovery from chronic liver damage [22–24]. Vismodegib functions as a small-molecule inhibitor of the hedgehog pathway by binding to smoothened (SMO) receptors in cells. Therefore, it may be reasonable to hypothesize that the damage caused by NASH creates an idiosyncratic trait within patients, placing them at a higher risk for experiencing a liver-based AE if they are treated with vismodegib as the drug attempts to regulate a highly damaged system.

Concomitant medication use, summarized in FAERS for 14 of the serious cases, may prove to be quite important, as four of the reports in FAERS indicated concomitant use of acetaminophen, a common over-the-counter medication (Table 1). Acetaminophen may lead to acute hepatotoxicity or necrosis, especially with overdose; acetaminophen poisoning accounts for nearly 50% of all cases of acute liver failure in the USA [25]. Ash and Jolly [26] reported a case of acute liver injury related to a possible drug–drug interaction between vismodegib, aspirin, and naproxen. Thus, concomitant drug use with vismodegib may contribute to drug–drug interactions that may play a major role in the development of liver toxicity.

The press announcement at the time of the original FDA approval on 30 January 2012 and the DailyMed website, on which full prescribing information documents are posted by the US National Library of Medicine, both specified that safety and effectiveness were not established for patients with hepatic impairment who receive vismodegib [27–29]. LiverTox currently lists vismodegib as a potentially hepatotoxic medication [30]. Health Canada has a statement similar to that of the FDA in relation to liver impairment but with an arrangement whereby the sponsor agrees to submit additional safety studies, specifically to include results from a renal/hepatic impairment study by March 2015 [31]. The European Medicines Agency (EMA) reported that data on moderate and severe liver impairment were too limited to enable conclusions about liver impairment, but nevertheless posted a table including abnormal liver enzymes as a common side effect in 1–10% of patients [32]. The Australian Government’s Therapeutic Goods Administration released a statement citing study SHH4489g, which attributed three cases of hepatotoxicity to vismodegib, cases resulted in hospitalizations, but no deaths were reported [33]. The agency recommended vismodegib be avoided in patients with severe hepatic impairment [33]. As such, although the FDA labeling (full prescribing information) mentions that medications that are liver metabolized should be avoided, it provides no information on drug interaction risks for vismodegib [27, 28]. Especially in light of healthcare system reform, busy health practitioners must access and utilize ever-increasing amounts of information in the prescribing of medications and patient management, with a continuous need for new and updated post-marketing risk information and newly identified clinically significant drug interactions [34].

In contrast with other drug regulatory agencies, the FDA has not yet advanced newly evolving risk information regarding vismodegib and hepatotoxicity, although it has issued recommendations for studies of vismodegib use in individuals with renal and liver dysfunction [29]. Patients with mild liver impairment should be carefully monitored if vismodegib is considered for therapy. We also recommend that potentially hepatotoxic agents such as acetaminophen and alcohol be avoided during vismodegib therapy.

Limits of this study may include under-reporting and potential reporting bias because of the voluntary nature of the FAERS database and the impracticability of contacting AE reporters. As such, the ability to establish causality of hepatotoxicity associated with vismodegib based on FAERS data is limited, albeit significant signal detection values were found.
5 Conclusion

Given a detectable safety signal for hepatotoxicity within FAERS for vismodegib, its use in patients with severe liver disease should include careful consideration of risk versus benefit. We recommend close monitoring of liver function and cautious use with concomitant hepatotoxic medications. As such, the FDA decision to waive Risk Evaluation and Mitigation Strategies (REMS) as part of its vismodegib labeling may require re-evaluation and carefully conducted prospective pharmacovigilance studies to achieve safe use. Rapid dissemination of such safety concerns is expected to result in fewer serious hepatotoxic adverse events and more optimal outcomes for patients with cancer receiving vismodegib.

Acknowledgements This research was supported by the University of Texas MD Anderson Cancer Center. The authors thank Dr. Franklin H. Herlong who provided insight and expertise that greatly assisted the research.

Author contributions Each author participated and contributed sufficiently to take public responsibility for appropriate portions of the content. Dr. Beatrice J. Edwards, Dr. HT Tran, and Dr. DP West made substantial contributions to study conception and design as well as the acquisition, analysis, and interpretation of the data. Dr. DW Raisch, Dr. SS Saraykar, Ms. M Sun, Dr. JA Hammel, N Wehr, and Dr. R Arabayt made substantial contributions to the acquisition, analysis, and interpretation of the data. All authors participated in drafting the article or critical revision for important intellectual content, provided final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

Compliance with Ethical Standards

Funding University of Texas MD Anderson Cancer Center.

Conflict of interest BJE, DWR, SSS, MS, JAH, HTT, NW, RA, and DPW have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9.
2. National Cancer Institute at the National Institutes of Health. Skin cancer. 2014. http://www.cancer.gov/cancertopics/types/skin. Accessed 20 Dec 2016.
3. Miller SJ, Alam M, Andersen J, Berg D, Bichakjian CK, Bowen G, et al. Basal cell and squamous cell skin cancers. J Natl Compr Cancer Netw. 2010;8(8):836–64.
4. Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. US Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289–93.
5. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.
6. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol. 2013;25(3):218–23.
7. Sanchez BE, Hajjafar L. Severe hepatotoxicity in a patient treated with hedgehog inhibitor: first case report. Gastroenterology. 2011;139(4):1264–5.
8. Caro I, Von Hoff DD, Mackey H, Reddy JC, Yauch RL. Clinical development of GDC-0449, a hedgehog pathway inhibitor, for the treatment of advanced basal cell carcinoma. J Am Acad Dermatol. 2010;1:AB104.
9. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. Phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509–18.
10. Council for International Organizations of Medical Sciences Working Group VIII. Practical aspects of signal detection in pharmacovigilance. Geneva: CIOMS; 2010.
11. Centers for Disease Control and Prevention (CDC). Cancer survivors: United States, 2007. MMWR Morb Mortal Wkly Rep. 2011;60(9):269–72.
12. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al. The research on adverse drug events and reports (RADAR) project. JAMA. 2005;293(17):2131–40.
13. Hauben M, Zhou X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 2003;26(3):159–86.
14. US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 28 May 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 30 Dec 2016.
15. Lammert C, Bjoransson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615–20.
16. Ventarola DJ, Silverstein DI. Vismodegib-associated hepatotoxicity: a potential side effect detected in postmarketing surveillance. J Am Acad Dermatol. 2014;71(2):397–8.
17. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.
18. Loewenberg S. The US comprehensive cancer centers in perspective. Mol Oncol. 2010;4(1):9–11.
19. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–9.
20. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(Suppl 1):S5–10.
21. Catenacci DV, Juntilla MK, Karlsson T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. Cancer J Clin Oncol. 2015;33(36):4284–92.
22. Ochoa B, Syn WK, Delgado I, Karaca GF, Jung Y, Wang J, et al. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology. 2010;51(5):1712–23.
23. Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012;34(10):2039–50.

24. Davey MG, McTeir L, Barrie AM, Freem LJ, Stephen LA. Loss of cilia causes embryonic lung hypoplasia, liver fibrosis, and cholestasis in the talpid ciliopathy mutant. Organogenesis. 2014;10(2):177–85.

25. Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 2004;40(1):6–9.

26. Ash MM, Jolly PS. Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. Int J Dermatol. 2015;54(3):370–4.

27. ERIVEDGE (vismodegib) capsule for oral use [package insert]. San Francisco, CA: Genentech USA, Inc.; Jan 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Accessed 26 June 2014.

28. US National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and research information on drug-induced liver injury. 28 Jun 2016. https://livertox.nlm.nih.gov. Accessed 14 July 2016.

29. Health Canada. Erivedge: summary basis of decision. 22 Aug 2013. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2013_erivedge_154608-eng.php. Accessed 26 June 2014.

30. US FDA; Center for Drug Evaluation and Research. Application number: 203388Orig1s000. Cross discipline team leader review. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203388Orig1s000CrossR.pdf. Accessed 10 Jan 2015.

31. European Medicines Agency. Erivedge 150 mg hard capsules [summary of product characteristics]. 30 July 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002602/WC500146817.pdf. Accessed 26 June 2014.

32. Australian Government Department of Health, Therapeutic Goods Administration. Australian Public Assessment Report: vismodegib. 21 Oct 2013. https://www.tga.gov.au/auspar/auspar-vismodegib. Accessed 26 June 2014.

33. de Leon J. Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol. 2011;31(3):263–5.